247 related articles for article (PubMed ID: 19411628)
1. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).
Kchour G; Tarhini M; Kooshyar MM; El Hajj H; Wattel E; Mahmoudi M; Hatoum H; Rahimi H; Maleki M; Rafatpanah H; Rezaee SA; Yazdi MT; Shirdel A; de Thé H; Hermine O; Farid R; Bazarbachi A
Blood; 2009 Jun; 113(26):6528-32. PubMed ID: 19411628
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
Hermine O; Dombret H; Poupon J; Arnulf B; Lefrère F; Rousselot P; Damaj G; Delarue R; Fermand JP; Brouet JC; Degos L; Varet B; de Thé H; Bazarbachi A
Hematol J; 2004; 5(2):130-4. PubMed ID: 15048063
[TBL] [Abstract][Full Text] [Related]
3. The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma.
Kchour G; Rezaee R; Farid R; Ghantous A; Rafatpanah H; Tarhini M; Kooshyar MM; El Hajj H; Berry F; Mortada M; Nasser R; Shirdel A; Dassouki Z; Ezzedine M; Rahimi H; Ghavamzadeh A; de Thé H; Hermine O; Mahmoudi M; Bazarbachi A
Retrovirology; 2013 Aug; 10():91. PubMed ID: 23962110
[TBL] [Abstract][Full Text] [Related]
4. Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma.
Nasr R; Marçais A; Hermine O; Bazarbachi A
Methods Mol Biol; 2017; 1582():197-216. PubMed ID: 28357672
[TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-alpha.
Mahieux R; Hermine O
Leuk Lymphoma; 2005 Mar; 46(3):347-55. PubMed ID: 15621824
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide (As
Marçais A; Cook L; Witkover A; Asnafi V; Avettand-Fenoel V; Delarue R; Cheminant M; Sibon D; Frenzel L; de Thé H; Bangham CRM; Bazarbachi A; Hermine O; Suarez F
Retrovirology; 2020 Mar; 17(1):5. PubMed ID: 32199462
[TBL] [Abstract][Full Text] [Related]
7. How I treat adult T-cell leukemia/lymphoma.
Bazarbachi A; Suarez F; Fields P; Hermine O
Blood; 2011 Aug; 118(7):1736-45. PubMed ID: 21673346
[TBL] [Abstract][Full Text] [Related]
8. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma.
White JD; Wharfe G; Stewart DM; Maher VE; Eicher D; Herring B; Derby M; Jackson-Booth PG; Marshall M; Lucy D; Jain A; Cranston B; Hanchard B; Lee CC; Top LE; Fleisher TA; Nelson DL; Waldmann TA
Leuk Lymphoma; 2001 Jan; 40(3-4):287-94. PubMed ID: 11426550
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.
Bazarbachi A; Plumelle Y; Carlos Ramos J; Tortevoye P; Otrock Z; Taylor G; Gessain A; Harrington W; Panelatti G; Hermine O
J Clin Oncol; 2010 Sep; 28(27):4177-83. PubMed ID: 20585095
[TBL] [Abstract][Full Text] [Related]
10. Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives.
Bazarbachi A; Hermine O
Virus Res; 2001 Oct; 78(1-2):79-92. PubMed ID: 11520582
[TBL] [Abstract][Full Text] [Related]
11. Long-term clinical remission maintained after cessation of zidovudine and interferon-α therapy in chronic adult T-cell leukemia/lymphoma.
Cook LB; Rowan AG; Demontis MA; Sagawe S; Gillet NA; Melamed A; Greiller C; Witkover A; Bangham CRM; Taylor GP
Int J Hematol; 2018 Mar; 107(3):378-382. PubMed ID: 29090417
[TBL] [Abstract][Full Text] [Related]
12. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma.
Hermine O; Allard I; Lévy V; Arnulf B; Gessain A; Bazarbachi A;
Hematol J; 2002; 3(6):276-82. PubMed ID: 12522449
[TBL] [Abstract][Full Text] [Related]
13. Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa.
Guery R; Suarez F; Lanternier F; Bougnoux ME; Lecuyer H; Avettand-Fenoel V; Sibon D; Frenzel L; Raphalen JH; Helias P; Renaudier P; Santa F; Lecuit M; Lortholary O; Hermine O; Aguilar C; Marçais A
Ann Hematol; 2021 Nov; 100(11):2813-2824. PubMed ID: 34387741
[TBL] [Abstract][Full Text] [Related]
14. Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1.
Brown M; Bellon M; Nicot C
Blood; 2007 Feb; 109(4):1653-9. PubMed ID: 17077332
[TBL] [Abstract][Full Text] [Related]
15. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia.
El Hajj H; El-Sabban M; Hasegawa H; Zaatari G; Ablain J; Saab ST; Janin A; Mahfouz R; Nasr R; Kfoury Y; Nicot C; Hermine O; Hall W; de Thé H; Bazarbachi A
J Exp Med; 2010 Dec; 207(13):2785-92. PubMed ID: 21135137
[TBL] [Abstract][Full Text] [Related]
16. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine.
Gill PS; Harrington W; Kaplan MH; Ribeiro RC; Bennett JM; Liebman HA; Bernstein-Singer M; Espina BM; Cabral L; Allen S
N Engl J Med; 1995 Jun; 332(26):1744-8. PubMed ID: 7760890
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells.
Bazarbachi A; El-Sabban ME; Nasr R; Quignon F; Awaraji C; Kersual J; Dianoux L; Zermati Y; Haidar JH; Hermine O; de Thé H
Blood; 1999 Jan; 93(1):278-83. PubMed ID: 9864171
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma.
Ishitsuka K; Suzumiya J; Aoki M; Ogata K; Hara S; Tamura K
Haematologica; 2007 May; 92(5):719-20. PubMed ID: 17488707
[TBL] [Abstract][Full Text] [Related]
19. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells.
Nasr R; Rosenwald A; El-Sabban ME; Arnulf B; Zalloua P; Lepelletier Y; Bex F; Hermine O; Staudt L; de Thé H; Bazarbachi A
Blood; 2003 Jun; 101(11):4576-82. PubMed ID: 12560223
[TBL] [Abstract][Full Text] [Related]
20. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.
Mone A; Puhalla S; Whitman S; Baiocchi RA; Cruz J; Vukosavljevic T; Banks A; Eisenbeis CF; Byrd JC; Caligiuri MA; Porcu P
Blood; 2005 Nov; 106(10):3380-2. PubMed ID: 16076875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
